CareDx, Inc. (CDNA)

Market Cap	1.01B -18.1%
Revenue (ttm)	358.00M +14.5%
Net Income	70.45M
EPS	1.22
Shares Out	51.43M
PE Ratio	16.16
Forward PE	21.93
Dividend	n/a
Ex-Dividend Date	n/a

Volume	463,937
Open	19.38
Previous Close	19.10
Day's Range	19.31 - 20.29
52-Week Range	10.96 - 25.55
Beta	2.51
Analysts	Buy
Price Target	26.67 (+35.86%)
Earnings Date	Feb 24, 2026

About CDNA

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to typ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jul 17, 2014
• Employees: 650
• Stock Exchange: NASDAQ
• Ticker Symbol: CDNA
• Website: https://caredx.com

Analyst Summary

According to 7 analysts, the average rating for CDNA stock is "Buy." The 12-month stock price target is $26.67, which is an increase of 35.86% from the latest price.

Price Target

$26.67

(35.86% upside)

Analyst Consensus: Buy